000298967 001__ 298967
000298967 005__ 20250819094356.0
000298967 0247_ $$2doi$$a10.1186/s13014-025-02594-y
000298967 0247_ $$2pmid$$apmid:39966902
000298967 037__ $$aDKFZ-2025-00396
000298967 041__ $$aEnglish
000298967 082__ $$a610
000298967 1001_ $$aHoffmeister-Wittmann, Paula$$b0
000298967 245__ $$aStereotactic body radiotherapy with carbon ions as local ablative treatment in patients with primary liver cancer.
000298967 260__ $$aLondon$$bBioMed Central$$c2025
000298967 3367_ $$2DRIVER$$aarticle
000298967 3367_ $$2DataCite$$aOutput Types/Journal article
000298967 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1755589411_6399
000298967 3367_ $$2BibTeX$$aARTICLE
000298967 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000298967 3367_ $$00$$2EndNote$$aJournal Article
000298967 520__ $$aLiver cancer is the third leading cause of cancer related death due to treatment resistance and late onset of symptoms (Rumgay in J Hepatol 77: 1598-1606, 2022). The role of external beam radiotherapy (EBRT) in treatment of unresectable liver cancer needs to be defined. The use of particle therapy such as carbon ion radiation therapy (CIRT) with high linear energy transfer (LET) could increase efficacy of EBRT while limiting the toxic effects of radiation on non-cancerous liver tissue. Promising effects of CIRT have been described in several studies during the past decades, mostly in Japan. To date, no standardized treatment protocol has been established and European data on CIRT for liver cancer is lacking. This retrospective analysis aims to investigate efficacy and safety of hypofractionated CIRT compared to photon-based stereotactic body radiation (SBRT) in primary liver cancer.Thirty-six (n = 36) and twenty (n = 20) patients with primary malignant liver tumors were treated with hypofractionated CIRT (4 fractions) and photon-based SBRT, respectively, between 2011 and 2022 and were retrospectively evaluated for survival, local control, and toxicity.Two-year local control rate after CIRT was 92.3%. Compared to photon- based SBRT, CIRT scores with a significantly longer median distant progression free survival (3.1 versus 0.9 years). In a matched pair comparison of the two treatment regimens, the CIRT cohort demonstrated both longer 2-year overall survival (100% versus 59.6%) and longer 2-year distant PFS (75.7% versus 22.9%). No significant impairment of liver function was observed in either cohort.In this retrospective analysis, patients who received CIRT presented excellent local tumor control and had better oncologic outcomes than patients who received photon-based SBRT. SBRT with carbon ions is a promising local ablative treatment option that needs further investigation in large prospective trials.
000298967 536__ $$0G:(DE-HGF)POF4-315$$a315 - Bildgebung und Radioonkologie (POF4-315)$$cPOF4-315$$fPOF IV$$x0
000298967 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000298967 650_7 $$2Other$$aCarbon ion radiotherapy
000298967 650_7 $$2Other$$aCholangiocarcinoma
000298967 650_7 $$2Other$$aHepatocellular carcinoma
000298967 650_7 $$2Other$$aHypofractionation
000298967 650_7 $$2Other$$aLocal control
000298967 650_7 $$2Other$$aSBRT
000298967 650_2 $$2MeSH$$aHumans
000298967 650_2 $$2MeSH$$aLiver Neoplasms: radiotherapy
000298967 650_2 $$2MeSH$$aRadiosurgery: adverse effects
000298967 650_2 $$2MeSH$$aRadiosurgery: methods
000298967 650_2 $$2MeSH$$aRetrospective Studies
000298967 650_2 $$2MeSH$$aHeavy Ion Radiotherapy: adverse effects
000298967 650_2 $$2MeSH$$aAged
000298967 650_2 $$2MeSH$$aMale
000298967 650_2 $$2MeSH$$aFemale
000298967 650_2 $$2MeSH$$aMiddle Aged
000298967 650_2 $$2MeSH$$aAged, 80 and over
000298967 650_2 $$2MeSH$$aSurvival Rate
000298967 650_2 $$2MeSH$$aAdult
000298967 650_2 $$2MeSH$$aCarcinoma, Hepatocellular: radiotherapy
000298967 650_2 $$2MeSH$$aCarcinoma, Hepatocellular: mortality
000298967 650_2 $$2MeSH$$aCarcinoma, Hepatocellular: pathology
000298967 7001_ $$0P:(DE-HGF)0$$aHoegen-Saßmannshausen, Philipp$$b1
000298967 7001_ $$aWicklein, Livia$$b2
000298967 7001_ $$0P:(DE-He78)c7f6680647a8e992f04c9e075784f775$$aWeykamp, Fabian$$b3$$udkfz
000298967 7001_ $$aSeidensaal, Katharina$$b4
000298967 7001_ $$aSpringfeld, Christoph$$b5
000298967 7001_ $$0P:(DE-He78)54a6641a6c26ddc49cc754740e90b438$$aDill, Michael$$b6$$udkfz
000298967 7001_ $$aLongerich, Thomas$$b7
000298967 7001_ $$aSchirmacher, Peter$$b8
000298967 7001_ $$aMehrabi, Arianeb$$b9
000298967 7001_ $$aMathy, René Michael$$b10
000298967 7001_ $$aKöhler, Bruno C$$b11
000298967 7001_ $$0P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDebus, Jürgen$$b12$$udkfz
000298967 7001_ $$aHerfarth, Klaus$$b13
000298967 7001_ $$aLiermann, Jakob$$b14
000298967 773__ $$0PERI:(DE-600)2224965-5$$a10.1186/s13014-025-02594-y$$gVol. 20, no. 1, p. 23$$n1$$p23$$tRadiation oncology$$v20$$x1748-717X$$y2025
000298967 909CO $$ooai:inrepo02.dkfz.de:298967$$pVDB
000298967 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000298967 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c7f6680647a8e992f04c9e075784f775$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000298967 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)54a6641a6c26ddc49cc754740e90b438$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000298967 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDeutsches Krebsforschungszentrum$$b12$$kDKFZ
000298967 9131_ $$0G:(DE-HGF)POF4-315$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vBildgebung und Radioonkologie$$x0
000298967 9141_ $$y2025
000298967 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bRADIAT ONCOL : 2022$$d2024-12-18
000298967 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-18
000298967 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-18
000298967 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2024-04-10T15:44:48Z
000298967 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2024-04-10T15:44:48Z
000298967 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2024-04-10T15:44:48Z
000298967 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-18
000298967 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-18
000298967 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-18
000298967 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-18
000298967 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-18
000298967 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-18
000298967 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-18
000298967 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2024-12-18
000298967 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2024-12-18
000298967 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2024-12-18
000298967 9201_ $$0I:(DE-He78)E050-20160331$$kE050$$lE050 KKE Strahlentherapie$$x0
000298967 9201_ $$0I:(DE-He78)D500-20160331$$kD500$$lNWG Experimentelle Hepatologie, Entzündung und Krebs$$x1
000298967 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x2
000298967 980__ $$ajournal
000298967 980__ $$aVDB
000298967 980__ $$aI:(DE-He78)E050-20160331
000298967 980__ $$aI:(DE-He78)D500-20160331
000298967 980__ $$aI:(DE-He78)HD01-20160331
000298967 980__ $$aUNRESTRICTED